Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBT (2019 - 2025)

Historic EBT for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.3 million.

  • Allogene Therapeutics' EBT rose 3659.72% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 2365.49%. This contributed to the annual value of -$257.1 million for FY2024, which is 2142.55% up from last year.
  • Latest data reveals that Allogene Therapeutics reported EBT of -$41.3 million as of Q3 2025, which was up 3659.72% from -$50.9 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year EBT high stood at $1.9 million for Q4 2021, and its period low was -$97.0 million during Q1 2023.
  • Its 5-year average for EBT is -$64.5 million, with a median of -$66.4 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first soared by 10276.07% in 2021, then plummeted by 504653.99% in 2022.
  • Allogene Therapeutics' EBT (Quarter) stood at $1.9 million in 2021, then tumbled by 5046.54% to -$93.6 million in 2022, then increased by 15.8% to -$78.8 million in 2023, then increased by 27.02% to -$57.5 million in 2024, then grew by 28.2% to -$41.3 million in 2025.
  • Its EBT stands at -$41.3 million for Q3 2025, versus -$50.9 million for Q2 2025 and -$59.8 million for Q1 2025.